Dr. Dana Lukin specializes in the care of patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. He completed medical and graduate training as well as residency in internal medicine at Mount Sinai School of Medicine, followed by fellowship training in gastroenterology at Columbia University Medical Center.
Dr. Lukin works closely with colleagues in affiliated specialties in order to provide comprehensive care for IBD patients as the Director of the Einstein-Montefiore Program for Inflammatory Bowel Diseases. He serves on the Chapter Medical Advisory Committee (CMAC) for the New York Chapter of the Crohn’s and Colitis Foundation of America (CCFA) as well as the CCFA Fellow’s Committee. He is a founding member of IBD-REMEDY (REsearch Mentoring EDucation new York) and serves on the Executive Committee of the New York Crohn’s and Colitis Organization (NYCCO).
With interests in clinical and translational research in IBD, Dr. Lukin is participating in several phase II and phase III Crohn’s disease and ulcerative colitis trials. His current translational research focuses on the microbiome in IBD as well as the role of indoles in intestinal permeability and signaling through the pregnane X receptor (PXR) and TLR4, funded by a pilot grant from the CCFA-Broad Medical Research Program.
Dulai PS, Singh S, Jiang X, Perrani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results from the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug; 111(8): 1147-55. doi: 10.1038/ajg.2016.236. Epub 2016 Jun 14.
Brave M, Lukin D, and Mani S. Microbial Control of Intestinal Innate Immunity. Oncotarget. 2015 [Epub ahead of print] PMID 26172839
Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, Mceachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S. Risk of New or Recurrent Cancer in Patients with Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-TNF Agents. Clin Gastroenterol Hepatol. 2015 Aug 3. [Epub ahead of print]. Pii: S1542-3565 (15)01052-6. PMID 26247164
Lukin DJ, Carvajal LA, Liu WJ, Resnick-Silverman L, Manfredi JJ. p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Mol Cancer Res. 2015 Jan;13(1):16-28. doi: 10.1158/1541-7786.MCR-14-0177. Epub 2014 Aug 26. PMID: 25158956
Lukin DJ and Swaminath AC. Case Report: Laryngeal Retention of a Video Capsule. Vis. Hum. J. Endoscopy. Volume 13, No. 1 (2014)
Westphalen CB, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, Brandtner A, Setlik W, Remotti H, Muley A, Chen X, May R, Houchen CW, Fox JG, Gershon MD, Quante M, Wang TC. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest. 2014 Mar;124(3):1283-95. PMID: 24487592
Hamard PJ, Lukin DJ, Manfredi JJ. p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes. J Biol Chem. 2012 Jun 22;287(26):22397-407. doi: 10.1074/jbc.M111.331298. Epub 2012 Apr 18. PMID: 22514277
Lukin DJ, Jandorf LH, Dhulkifl RJ, Thélémaque LD, Christie JA, Itzkowitz SH, Duhamel KN. Effect of comorbid conditions on adherence to colorectal cancer screening. J Cancer Educ. 2012 Jun;27(2):269-76. doi: 10.1007/s13187-011-0303-2. PMID: 22351374